[
  {
    "ts": null,
    "headline": "Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States",
    "summary": "INCHEON, Korea, July 17, 2025--Samsung Bioepis Co., Ltd. (\"Samsung Bioepis\") announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (Nasdaq: HROW), for Samsung Bioepis’ ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTISi (ranibizumab) and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEAii (aflibercept) — in the United States. The commercial license will become effective upon comple",
    "url": "https://finnhub.io/api/news?id=5062ad2118d41e98ac0b6f0ab7e0197b6bde1b0c1cdf74a11f3f48b8ed5d9071",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752750000,
      "headline": "Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States",
      "id": 135994660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "INCHEON, Korea, July 17, 2025--Samsung Bioepis Co., Ltd. (\"Samsung Bioepis\") announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (Nasdaq: HROW), for Samsung Bioepis’ ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTISi (ranibizumab) and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEAii (aflibercept) — in the United States. The commercial license will become effective upon comple",
      "url": "https://finnhub.io/api/news?id=5062ad2118d41e98ac0b6f0ab7e0197b6bde1b0c1cdf74a11f3f48b8ed5d9071"
    }
  },
  {
    "ts": null,
    "headline": "Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States",
    "summary": "NASHVILLE, July 17, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter \"Samsung Bioepis\") to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referenc",
    "url": "https://finnhub.io/api/news?id=bd7c73d9a085d7a907dc288c201c9220699f395b83793b18a2c15d9cc262531c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752750000,
      "headline": "Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States",
      "id": 135994659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "NASHVILLE, July 17, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter \"Samsung Bioepis\") to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referenc",
      "url": "https://finnhub.io/api/news?id=bd7c73d9a085d7a907dc288c201c9220699f395b83793b18a2c15d9cc262531c"
    }
  }
]